| RANK-RANKL-OPG系统及其治疗骨质疏松相关药物的研究进展 |
| |
| 引用本文： | 郭宇航,何成.RANK-RANKL-OPG系统及其治疗骨质疏松相关药物的研究进展[J].国际生物制品学杂志,2022,45(4):222-227. |
| |
| 作者姓名： | 郭宇航 何成 |
| |
| 作者单位： | 上海生物制品研究所有限责任公司第二研究室，上海 200051 |
| |
| 摘 要： | 骨骼是一种动态组织，由大约70%的矿物质和30%的有机成分组成，并通过持续的骨形成和骨吸收来维持。骨形成和骨吸收障碍可导致代谢性骨病，如骨坏死和骨质疏松症等。相关研究结果表明，骨保护素（osteoprotegerin，OPG）、核因子κB受体活化因子（receptor activator of nuclear factor-κB，RANK）及其配体（RANK ligand，RANKL）相关细胞因子参与或调节这一动态平衡。此文就RANK-RANKL-OPG系统及其治疗骨质疏松相关药物的研究进展作一综述。
|
| 关 键 词： | 骨保护素 核因子κB受体活化因子 核因子κB受体活化因子配体 骨质疏松 |
Research progress of RANK-RANKL-OPG system and related drugsfor treatment of osteoporosis |
| |
| Institution: | No. 2 Research Laboratory, Shanghai Institute of Biological Products Co., Ltd., Shanghai 200051, China
|
| |
| Abstract: | Bone is a dynamic tissue, composed of approximately 70% minerals and 30% organic components, formed and maintained through continuous bone formation and absorption. Disorders of bone formation and resorption lead to metabolic bone diseases such as osteonecrosis and osteoporosis. Related research results show that osteoprotegerin (OPG), receptor activator of nuclear factor-κB(RANK) and RANK ligand(RANKL) related cytokines participate in or regulate this dynamic balance. This article reviews the research progress of RANK-RANKL-OPG system and related drugs for treatment of osteoporosis . |
| |
| Keywords: | Osteoprotegerin Receptor activator of nuclear factor kappa B Receptor activator of nuclear factor kappa B ligand Osteoporosis |
|
| 点击此处可从《国际生物制品学杂志》浏览原始摘要信息 |
| 点击此处可从《国际生物制品学杂志》下载免费的PDF全文 |
